Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 88Rituximab 76Specimen Handling 75Magnetic Resonance Spectroscopy 64Biopsy 60Vincristine 49Doxorubicin 48Prednisone 45venetoclax 38obinutuzumab 34fludarabine 32Lenalidomide 29ibrutinib 28Cytarabine 27Dexamethasone 26Methotrexate 25prednylidene 23Etoposide 23zanubrutinib 22deltacortene 22CT-P10 22blinatumomab 21acalabrutinib 21Nivolumab 21fludarabine phosphate 19merphos 18Bendamustine Hydrochloride 17Calcium Dobesilate 16pembrolizumab 15X-Rays 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panzyga × Lymphoid × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡